Medicare Enrolled
Dr. Bhavesh Balar, MD
Hematology & Oncology · Freehold, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Balar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Balar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Balar
Dr. Bhavesh Balar is a hematology & oncology specialist in Freehold, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Balar performed 229,726 Medicare services across 6,678 unique beneficiaries.
Between the years covered by Open Payments, Dr. Balar received a total of $11,871 from 86 pharmaceutical and/or device companies across 672 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Balar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in NJ
$11,871 industry payments
Medicare Practice Summary
Medicare Utilization ↗229,726
Medicare services
Top 1% in NJ for hematology & oncology
6,678
Unique beneficiaries
$18
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~11,486 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Nivolumab injection (Opdivo) | 36,240 | $24 | $73 |
| Pembrolizumab injection (Keytruda) | 32,200 | $43 | $135 |
| Injection, granisetron, extended-release, 0.1 mg | 19,300 | $5 | $17 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
17,772 | $0 | $24 |
| Denosumab injection (Prolia/Xgeva) | 16,500 | $18 | $61 |
| Anti-nausea injection (aprepitant) | 15,340 | $1 | $7 |
| Iron infusion (Monoferric) | 13,800 | $17 | $68 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
8,601 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
8,361 | $6 | $54 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
7,880 | $6 | $27 |
| Paclitaxel chemotherapy injection | 6,540 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,700 | $0 | $6 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
4,270 | $36 | $183 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,080 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
3,599 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,567 | $8 | $32 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,680 | $22 | $180 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,030 | $102 | $231 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,806 | $25 | $129 |
| Injection, leucovorin calcium, per 50 mg | 1,791 | $3 | $23 |
| Anti-nausea injection (ondansetron/Zofran) | 1,496 | $0 | $3 |
| Injection, atropine sulfate, 0.01 mg | 1,465 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 1,280 | $0 | $19 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,183 | $2 | $11 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,130 | $12 | $84 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,102 | $13 | $88 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
1,091 | $1 | $13 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
965 | $1 | $5 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
912 | $108 | $919 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
847 | $113 | $578 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
800 | $99 | $232 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
750 | $146 | $305 |
| Injection, irinotecan, 20 mg | 534 | $2 | $160 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
485 | $72 | $154 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
425 | $55 | $270 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
416 | $61 | $195 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
348 | $2 | $207 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
232 | $1 | $15 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
224 | $145 | $416 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
205 | $57 | $282 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
195 | $24 | $127 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
191 | $18 | $82 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
179 | $7 | $398 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
168 | $97 | $263 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
158 | $66 | $182 |
| New patient office visit, complex (60-74 min) | 129 | $178 | $438 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
122 | $21 | $93 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
117 | $49 | $250 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
106 | $150 | $812 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
104 | $4 | $26 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
73 | $17 | $78 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
70 | $28 | $118 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
42 | $11 | $69 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
35 | $3 | $12 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
25 | $81 | $248 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
23 | $2 | $16 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $46 | $92 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
20 | $124 | $351 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.4% high complexity
84.8% medium
5.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,871
Total received (2018-2024)
Avg $1,696/year across 7 years
Top 24% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
86
Companies
672
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,380 (87.4%)
Other
Charitable contributions, space rental, and other categories
$1,419 (12.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$72 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,105
2023
$2,471
2022
$2,262
2021
$1,458
2020
$698
2019
$1,016
2018
$861
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,120
Daiichi Sankyo Inc.
$259
PFIZER INC.
$141
Stryker Corporation
$115
Eisai Inc.
$110
ABBVIE INC.
$106
Janssen Biotech, Inc.
$105
Gilead Sciences, Inc.
$82
E.R. Squibb & Sons, L.L.C.
$80
Celgene Corporation
$79
BeiGene USA, Inc.
$65
Incyte Corporation
$65
Astellas Pharma US Inc
$61
Pharmacosmos Therapeutics Inc.
$58
Merck Sharp & Dohme LLC
$57
GlaxoSmithKline, LLC.
$54
Bayer Healthcare Pharmaceuticals Inc.
$48
Adaptive Biotechnologies Corporation
$40
SERVIER PHARMACEUTICALS LLC
$37
AstraZeneca Pharmaceuticals LP
$36
GENZYME CORPORATION
$35
Regeneron Healthcare Solutions, Inc.
$34
Alnylam Pharmaceuticals Inc.
$28
Rigel Pharmaceuticals, Inc.
$26
Genentech USA, Inc.
$22
TAIHO ONCOLOGY, INC.
$22
Stemline Therapeutics Inc.
$21
SUN PHARMACEUTICAL INDUSTRIES INC.
$20
Acrotech Biopharma Inc.
$19
SpringWorks Therapeutics, Inc.
$19
Tempus AI, Inc
$18
JAZZ PHARMACEUTICALS INC.
$16
EMD Serono, Inc.
$16
Geron Corporation
$16
Coherus Biosciences Inc.
$16
ARRAY BIOPHARMA INC
$15
Octapharma USA, Inc.
$15
Mirati Therapeutics, Inc.
$15
Lilly USA, LLC
$14
Top 3 companies account for 49.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,060
E.R. Squibb & Sons, L.L.C.
$805
PFIZER INC.
$492
Daiichi Sankyo Inc.
$459
Merck Sharp & Dohme Corporation
$422
Merck Sharp & Dohme LLC
$366
Janssen Biotech, Inc.
$350
Genentech USA, Inc.
$345
Celgene Corporation
$340
Seagen Inc.
$325
Eisai Inc.
$301
GENZYME CORPORATION
$301
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Amgen Inc.
$256
GlaxoSmithKline, LLC.
$253
Gilead Sciences, Inc.
$243
Astellas Pharma US Inc
$243
Incyte Corporation
$241
Bayer HealthCare Pharmaceuticals Inc.
$225
AstraZeneca Pharmaceuticals LP
$214
EMD Serono, Inc.
$162
ABBVIE INC.
$147
Pharmacosmos Therapeutics Inc.
$126
Stryker Corporation
$115
Kite Pharma, Inc.
$111
Coherus Biosciences Inc.
$109
AbbVie Inc.
$99
Cook Medical LLC
$96
Bayer Healthcare Pharmaceuticals Inc.
$95
Adaptive Biotechnologies Corporation
$93
BeiGene USA, Inc.
$92
ARRAY BIOPHARMA INC
$88
Array BioPharma Inc.
$83
Pharmacyclics LLC, An AbbVie Company
$74
Janssen Pharmaceuticals, Inc
$74
SERVIER PHARMACEUTICALS LLC
$70
Seattle Genetics, Inc.
$69
Dendreon Pharmaceuticals LLC
$68
Regeneron Healthcare Solutions, Inc.
$68
Exelixis Inc.
$64
Blueprint Medicines Corporation
$63
Takeda Pharmaceuticals U.S.A., Inc.
$62
Epizyme, Inc.,
$60
EISAI INC.
$59
Apellis Pharmaceuticals, Inc.
$58
JAZZ PHARMACEUTICALS INC.
$57
AbbVie, Inc.
$49
AVEO Pharmaceuticals, Inc.
$48
SUN PHARMACEUTICAL INDUSTRIES INC.
$46
PUMA BIOTECHNOLOGY, INC.
$46
Novocure Inc.
$45
G1 Therapeutics, Inc.
$45
Mirati Therapeutics, Inc.
$44
Kyowa Kirin, Inc.
$42
Boehringer Ingelheim Pharmaceuticals, Inc.
$40
Stemline Therapeutics Inc.
$40
TAIHO ONCOLOGY, INC.
$39
Octapharma USA, Inc.
$35
Acrotech Biopharma LLC
$34
Puma Biotechnology, Inc.
$31
Ipsen Biopharmaceuticals, Inc
$30
MorphoSys, US Inc.
$29
Karyopharm Therapeutics Inc.
$29
Alnylam Pharmaceuticals Inc.
$28
Pharmacyclics LLC, an AbbVie Company
$28
Rigel Pharmaceuticals, Inc.
$26
Spectrum Pharmaceuticals Inc.
$23
Acrotech Biopharma Inc.
$19
Sun Pharmaceutical Industries Inc.
$19
SpringWorks Therapeutics, Inc.
$19
Tempus AI, Inc
$18
Sumitomo Pharma America, Inc.
$17
Myovant Sciences Inc.
$17
Alexion Pharmaceuticals, Inc.
$17
Genmab U.S., Inc.
$16
Geron Corporation
$16
Verity Pharmaceuticals Inc.
$16
Horizon Therapeutics plc
$15
Deciphera Pharmaceuticals Inc.
$14
Shire North American Group Inc
$14
SANOFI-AVENTIS U.S. LLC
$14
Lilly USA, LLC
$14
Helsinn Therapeutics (U.S.), Inc.
$14
Acceleron Pharma, Inc.
$13
Foundation Medicine, Inc.
$12
Secura Bio, Inc.
$11
Top 3 companies account for 28.3% of all-time payments
Associated products mentioned in payments ›
1788 · ABECMA · ADCETRIS · AYVAKIT · Abraxane · Alecensa · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CEREZYME · COSELA · Cabometyx · DARZALEX · ELAHERE · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · EXKIVITY · Empaveli · Enhertu · Epkinly · Erleada · FARYDAK · FOLOTYN · FOTIVDA · FOUNDATIONONE · GAZYVA · GILOTRIF · GIVLAARI · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · Monoferric · NERLYNX · NINLARO · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Oncology · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYTELO · Reblozyl · Revlimid · Rezlidhia · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SUTENT · Stivarga · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TUKYSA · Tibsovo · Trelstar · Trodelvy · ULTOMIRIS · Udenyca · VALCHLOR · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · WILATE · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZENITH · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
86
Per 100K population
13.4
County median income
$122,727
Nearest hospital
CENTRASTATE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Balar is a mixed practice specialist, with above-average Medicare volume (top 1% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Balar experienced with nivolumab injection (opdivo)?
Based on Medicare claims data, Dr. Balar performed 36,240 nivolumab injection (opdivo) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Balar receive payments from pharmaceutical companies?
Yes. Dr. Balar received a total of $11,871 from 86 companies across 672 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Balar's costs compare to other hematology & oncology specialists in Freehold?
Dr. Balar's average Medicare payment per service is $18. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Balar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Freehold
Browse hematology & oncology specialists in Freehold ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology